Takeda Pharmaceutical Company (TAK +1.2%) announces positive results from a Phase 3 clinical trial, TOURMALINE-MM4, evaluating Ninlaro (ixazomib) as first-line maintenance therapy in adult multiple myeloma patients who have not received stem cell transplantation. The study met the primary endpoint of progression-free survival versus placebo.
The company says this is the first industry-sponsored study to explore “switch” maintenance, the use of medicines not included in initial induction therapy.
No new safety signals were observed.
Final results will be submitted for presentation at a future medical conference.
Ninlaro is not currently approved for this use.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.